bioMérieux: CE marking for head injury test
(CercleFinance.com) - bioMérieux announces the CE marking of VIDAS TBI (GFAP, UCH-L1), a blood test for the evaluation and management of patients with mild head traumas, including concussion.
This diagnostic tool can help to limit the number of brain scans (CT) and relieve emergency room overcrowding by detecting the absence of post-traumatic intracranial lesions, the in vitro diagnostics specialist said.
The test's marketing will begin in Q4 2023 in Europe, North Africa and South America. Deployment in the rest of the world will be phased in over 2024 and 2025.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
This diagnostic tool can help to limit the number of brain scans (CT) and relieve emergency room overcrowding by detecting the absence of post-traumatic intracranial lesions, the in vitro diagnostics specialist said.
The test's marketing will begin in Q4 2023 in Europe, North Africa and South America. Deployment in the rest of the world will be phased in over 2024 and 2025.
Copyright (c) 2023 CercleFinance.com. All rights reserved.